Proof of the concept of the latter has been provided for decades in patients with hemophilia, long before the role of thrombin activatable fibrinolytic inhibitor.
Possible interactions between deficiencies of FXIII and thrombin-activatable fibrinolytic inhibitorThrombin-activatable fibrinolytic inhibitor (TAFI), a single-chain carboxypeptidase B–like zymogen, is activated by thrombin to become activated TAFI (TAFIa). [62] The importance of TAFIa in fibrinolysis is emphasized by the fact that the conversion of only 1% of the zymogen to TAFIa is sufficient to suppress fibrinolysis by approximately 60%.